Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE 2: IcoSema versus semaglutide in adults with type 2 diabetes previously treated with a GLP-1 receptor agonist
jRCT2051220044Completed
- Sponsor
- Novo Nordisk
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM) comparing IcoSema once weekly with semaglutide once weekly (2 arms). Primary endpoint: Change in HbA1c. Started May 2022; status: completed.
02
Drugs
icosemasemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2051220044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220044.